Scientific articleLong-term complete remission inbladder carcinoma in situ with intravesical tice bacillus Calmette guerin: Overview analysis of six phase II clinical trials
References (29)
- et al.
The plight of the patient with carcinoma in situ of the bladder
J Urol
(1970) - et al.
Contemporary cystectomy pelvic node dissection compared to preoperative radiation therapy plus cystectomy in the management of invasive bladdercancer
J Urol
(1984) - et al.
Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors
J Urol
(1976) Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results
J Urol
(1985)- et al.
Bacillus Calmette-Guerin for therapy of superficial transitional cell carcinoma of the bladder
J Urol
(1986) Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder
J Urol
(1986)Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer
J Urol
(1984)Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder
J Urol
(1986)Bacillus Calmette-Guerin immunotherapy for bladder cancer
J Urol
(1985)Single-course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial
J Urol
(1987)
Retrospective study of efficacy of intravesical BCG alone in the treatment of superficial bladder cancer
Urology
The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin
J Urol
The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ
J Urol
Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C
J Urol
Cited by (78)
Immunotherapy
2018, Bladder CancerImmunotherapy: Bacille Calmette-Guérin
2017, Bladder CancerNatural product derived immune-regulatory agents
2016, International ImmunopharmacologyCitation Excerpt :Treatment with BCG delays progression to muscle-invasive and/or metastatic disease, improves bladder preservation, and decreases the risk of death from bladder cancer [16]. Although intravesical BCG may not prolong overall survival (OS) for carcinoma in situ, it does result in complete response rates of about 70%, decreasing the need for salvage cystectomy [17] and delaying tumor recurrence and progression [18]. Meta-analyses have documented that BCG reduces recurrence and progression rates [19] and in comparison to IFN-α has similar efficacy [20].
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review
2015, European UrologyCitation Excerpt :As with all high-risk NMIBC, a balance must be struck between overtreatment with RC and undertreatment with subsequent disease progression when administering BCG [2,75,90]. It has not been demonstrated that an initial trial of BCG immunotherapy, followed by salvage RC for patients who fail to achieve a CR or who recur, affects overall survival compared with immediate RC [91–93]. However, progression to invasive disease likely occurs in a delayed fashion in patients with CIS.
Novel Clinical Trials and Approaches in the Management of Glioblastoma
2024, Current Oncology Reports